Skip to main content
Premium Trial:

Request an Annual Quote

Ignyta Buys Personalized Medicine Firm Actagene

NEW YORK (GenomeWeb News) – Ignyta said on Monday it has acquired biotech firm Actagene for an undisclosed amount.

The deal, according to Ignyta, will transition it from a company focused solely on molecular diagnostics for autoimmune diseases to "an integrated Rx/Dx focus on drug and biomarker discovery and development for cancer and immunology."

Actagene was founded this past February and like Ignyta is headquartered in San Diego. It developed personalized medicines for "high unmet need cancer indications, based on cancer genome mining and sequencing," Ignyta said. It has a proprietary database called Oncolome, which it applies along with other technologies such as synthetic lethal screening, X-ray crystallography, and structure-based drug design to develop new chemical entities against genetic targets that in certain cancer populations are enriched.

As part of the deal, a number of Actagene's executives will join Ignyta, including CEO Patrick O'Connor, who will become CSO and SVP, head of research at Ignyta.

"The Actagene acquisition provides Ignyta with a strategic entry into oncology personalized medicine, an area with high unmet medical need and opportunities to give patients customized treatment options that leverage Ignyta's biomarker discovery capabilities," Ignyta Chairman and CEO Jonathan Lim said in a statement.

In February Ignyta announced a $1.1 million loan facility, and month prior to that it raised $5.5 million in a Series B financing round.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.